Peripheral T-cell lymphoma (PTCL) is an aggressive tumor derived from mature T cells and natural killer cells with an extremely poor prognosis. Ferroptosis is a mechanism of cell death that is ...

In other words, transient CAR-mediated CD4 + depletion would be used as a short-term 'bridge to transplant ... PTCLs and other T-cell malignancies. Human lymphoma cells and peripheral blood ...

The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B ...

Peripheral T-cell lymphomas (PTCLs) represent approximately 12% of all lymphoid tumors worldwide. The vast majority of them belong to the not otherwise specified (NOS) angioimmunoblastic or ...

Other lymphomas, such as peripheral T-cell lymphoma ... and stem cell transplant. Some forms of T-cell lymphoma, especially if it is slow growing, may not receive any treatment.

Fig 1. Schema. BV, brentuximab vedotin; CAR-T, chimeric antigen receptor T-cell therapy; DLBCL, diffuse large B-cell lymphoma; Len, lenalidomide; R, rituximab; R/R, relapsed/refractory; SCT, stem-cell ...

My research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin ...

My particular expertise is in the area of allogeneic transplantation — the use of stem cells or bone marrow derived from a donor other than the patient. Stem cells can come from different sources ...

There is no standard therapeutic regimen for patients with relapsed or refractory FL. Many options exist, and factors to consider include knowledge of previous therapies and their efficacy ...